1. Protection of Chickens against H9N2 Avian Influenza Isolates with a Live Vector Vaccine Expressing Influenza Hemagglutinin Gene Derived from Y280 Avian Influenza Virus.
- Author
-
Zhang, Jun-Feng, Kim, Sang-Won, Shang, Ke, Park, Jong-Yeol, Choi, Yu-Ri, Jang, Hyung-Kwan, Wei, Bai, Kang, Min, and Cha, Se-Yeoun
- Subjects
CHICKEN diseases ,AVIAN influenza A virus ,AVIAN influenza ,INFLUENZA vaccines ,HEMAGGLUTININ ,VIRUS isolation ,HUMORAL immunity - Abstract
Simple Summary: The H9N2 subtype of avian influenza virus (AIV) was first identified in turkey flocks in Wisconsin, USA, in 1966. Since then, H9N2 AIVs have been detected in mammals, domestic poultry, and wild birds. In June 2020, a new H9N2/Y280 was discovered in Korea. Existing commercial vaccines might not be fully effective against H9N2/Y280. Since influenza viruses undergo mutations rapidly, fast and accurate vaccine production is critical to address variant strains. Consequently, this study focused on rapid and effective vaccine production techniques against H9N2/Y280. The recombinant rHVT/Y280 was successfully constructed using NHEJ-CRISPR/Cas9 gene-editing technology. rHVT/Y280 vaccination induced strong humoral immunity, providing significant protection against H9N2/Y280 strain A21-MRA-003 following a challenge of 2 × 10
7 50% egg infectious dose. Therefore, rHVT/Y280 is a potential candidate for a live vaccine against H9N2/Y280. Since the outbreak of the H9N2/Y439 avian influenza virus in 1996, the Korean poultry industry has incurred severe economic losses. A novel possibly zoonotic H9N2 virus from the Y280-like lineage (H9N2/Y280) has been prevalent in Korea since June 2020, posing a threat to the poultry sector. Rapid mutation of influenza viruses urges the development of effective vaccines against newly generated strains. Thus, we engineered a recombinant virus rHVT/Y280 to combat H9N2/Y280. We integrated the hemagglutinin (HA) gene of the H9N2/Y280 strain into the US2 region of the herpesvirus of turkeys (HVT) Fc126 vaccine strain, utilizing CRISPR/Cas9 gene-editing technology. The successful construction of rHVT/Y280 was confirmed by polymerase chain reaction and sequencing, followed by efficacy evaluation. Four-day-old specific pathogen-free chickens received the rHVT/Y280 vaccine and were challenged with the H9N2/Y280 strain A21-MRA-003 at 3 weeks post-vaccination. In 5 days, there were no gross lesions among the vaccinated chickens. The rHVT/Y280 vaccine induced strong humoral immunity and markedly reduced virus shedding, achieving 100% inhibition of virus recovery in the cecal tonsil and significantly lowering tissue viral load. Thus, HVT vector vaccines expressing HA can be used for protecting poultry against H9N2/Y280. The induction of humoral immunity by live vaccines is vital in such cases. In summary, the recombinant virus rHVT/Y280 is a promising vaccine candidate for the protection of chickens against the H9N2/Y280. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF